Experiment

CLINICAL PIPELINE

Longeveron is focused on developing cellular therapy primarily for chronic aging-related diseases, and other life-threatening conditions, for which there is a clear unmet medical need.

Our mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.

*Hover over each trial to learn more
Alzheimer's
Disease
Phase 1
Phase 2
Phase 3
Funding/Partner

Alzheimer's Disease

ALZHEIMER ASSOCIATION.png
Phase 1 single infusion safety study complete. Phase 2 multi-dose study to initiate in 2021.
Aging Frailty
Phase 1
Phase 2
Phase 3
Funding/Partner

Aging Frailty Phase 2b

NIH.png
Enrollment complete. Subject follow up ongoing.
TEDCO.png
Enrollment complete. Subject follow up ongoing.
NIH.png
Sub-study of US Frailty trials.

Aging Frailty (Japanese Phase 2 Study)

Initiate Phase 2 trial in 2021.
Acute Respiratory Distress Syndrome (ARDS)
Phase 1
Phase 2
Phase 3
Funding/Partner
TEDCO.png
Trial enrolling.
Hypoplastic Left Heart Syndrome (HLHS)
Phase 1
Phase 2
Phase 3
Funding/Partner
TEDCO.png
download.png
Initiate Phase 2 trial in 2021.
Bahamas Treatment Registry Trial

Bahamas Treatment Registry Trial

We sponsor a Treatment Registry Trial in The Bahamas under the approval and authority of the National Stem Cell Ethics Committee (NSCEC). Eligible participants for the Registry may receive Lomecel-B at their own expense at one of two private partner clinics in Nassau for NSCEC-approved indications: Frailty, mild cognitive impairment, Alzheimer’s Disease and related dementias, and osteoarthritis. Lomecel-B is not an approved product in The Bahamas or the United States, and is considered an investigational therapeutic. For more information about this program please contact us.
Scientist%20on%20Computer_edited.jpg

Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience: a profound decline in our own MSCs; a decrease in immune system function, known as immunosenescence; diminished blood vessel functioning; chronic inflammation, known as “inflammaging”; and other aging-related declines. Our clinical data suggest that Lomecel-B addresses these problems through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.


Improving healthspan is an imperative for governmental health agencies, and the NIA, an institute of the NIH, has promoted the concept of geroscience – the idea that aging itself is the biggest risk factor for aging-related human diseases. The geroscience hypothesis provides a strong rationale for the approach of treating underlying biological processes contributing to aging as a way to reduce disease burden and advance global human health. Our investments into developing and testing product candidates are aimed at reducing aging-related disease burden and improving healthspan.